Enteropathy secondary to olmesartan therapy results from the drug’s ability to induce T-cell activation and dysregulate cytokines, including tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ). The gene discussed is TNF; the disease is Abnormal intestine morphology.